Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06410248 · ClinicalTrials.gov registry record · Phase 1

Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma

A Phase 1 study of Recurrent Glioblastoma, IDH-Wildtype and Recurrent WHO Grade 4 Glioma, sponsored by Northwestern University.

Active
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT06410248 is a Phase 1 study of Recurrent Glioblastoma, IDH-Wildtype and Recurrent WHO Grade 4 Glioma that is active but no longer recruiting, run by Northwestern University. The registered enrollment target is 30 participants, below the 38-participant average among 4 other Recurrent Glioblastoma, IDH-Wildtype trials with a reported enrollment target (21% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06410248, a Phase 1 study of Recurrent Glioblastoma, IDH-Wildtype and Recurrent WHO Grade 4 Glioma, is active but no longer recruiting, sponsored by Northwestern University.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This phase I trial tests the safety, side effects, and best dose of triapine in combination with temozolomide in treating patients with glioblastoma that has come back after a period of improvement (recurrent). Triapine inhibits an enzyme responsible for producing molecules required for the production of deoxyribonucleic acid (DNA), which may inhibit tumor cell growth. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Giving triapine in combination with temozolomide may be safe, tolerable, and/or effective in treating patients with recurrent glioblastoma.

Conditions Studied

Recurrent Glioblastoma, IDH-Wildtype Recurrent WHO Grade 4 Glioma Recurrent WHO Grade 2 Glioma Recurrent WHO Grade 3 Glioma

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Magnetic Resonance Imaging
  • OTHER Questionnaire Administration
  • DRUG Temozolomide
  • PROCEDURE Resection

Study Locations (1)

Illinois

  • Northwestern University - Chicago

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-07-23
Est. Completion 2030-05-12
Phase Phase 1

Sponsor

Northwestern University

1,209 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06410248

The ClinicalTrials.gov registry entry for NCT06410248 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 38-participant average among 4 other Recurrent Glioblastoma, IDH-Wildtype trials with a reported enrollment target (21% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Recurrent Glioblastoma, IDH-Wildtype appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT06410248 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT06410248 about?

NCT06410248 is a clinical study titled "Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma". This phase I trial tests the safety, side effects, and best dose of triapine in combination with temozolomide in treating patients with glioblastoma that has come back after a period of improvement (recurrent). Triapine inhibits an enzyme responsible for producing molecules required for the producti...

What is the current status of trial NCT06410248?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2024-07-23. Estimated completion is 2030-05-12.

What conditions does trial NCT06410248 study?

This clinical trial studies the following conditions: Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 4 Glioma, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma.

What interventions are being tested in trial NCT06410248?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Questionnaire Administration (OTHER), Temozolomide (DRUG), Resection (PROCEDURE).

Who is sponsoring clinical trial NCT06410248?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06410248 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Glioblastoma, IDH-Wildtype

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Glioblastoma, IDH-Wildtype

All registered trials for this condition

Recurrent WHO Grade 4 Glioma

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.